inhibit erythropoiesis [3] . Elevated levels of erythropoietin, originating mainly from native kidneys, contribPurpose of study. To evaluate the effect of the angiotensin II type 1 receptor antagonist, losartan, on ute to this problem in~50% of patients [5] . Other mechanisms, such as altered regulation of the haemapost-transplant erythrocytosis. Methods. We retrospectively analyzed the influence of tocrit-erythropoietin feedback system and enhanced sensitivity of bone marrow precursors to erythropoielosartan therapy on haemoglobin levels of renal transplant recipients. Twenty-eight patients who received tin, have been reported [6, 7] .
Introduction
our study. Ten of these 28 patients had received ACE inhibitors prior to the use of losartan therapy (Group A).
Post-transplant erythrocytosis (PTE ), defined as a The data from Group A were analysed separately from the persistently elevated haematocrit (>0.51), develops in remaining 18 patients who had never received ACE inhibitor 9-22% of renal transplant recipients [1] [2] [3] . It occurs therapy (Group B). All but two patients in each group most commonly during the first 2 years after renal received triple immunosuppressive therapy which included transplantation in hypertensive males with excellent steroids, azathioprine, and cyclosporine. The remaining four allograft function [4] . PTE appears to occur more received double immunosuppressive therapy with steroids and azathioprine.
frequently with the use of cyclosporine, possibly due A decrease in haematocrit beginning at 6 weeks, and with to the inhibition of the production of cytokines which a maximum response at 3 months after the onset of ACE inhibitor therapy has been reported. Therefore, we evaluated obtained at the beginning of losartan therapy and 3 months Each set of data was designated 1 at the beginning of losartan therapy and 2 three months later. Each set of data was designated 1 at the beginning of losartan therapy and 2 three months later. mean haemoglobin concentration and haematocrit did not significantly change from the beginning of losartan therapy to 3 months post-treatment; 131±13 g/l vs
Results
134±15 g/l (NS) and 0.37 vs 0.38, respectively. In Group B, mean haemoglobin concentration decreased from 137±20 g/l at the start of losartan therapy to A summary of the patient characteristics are listed in Tables 1 and 2 . Mean haemoglobin concentrations 120±16 g/l 3 months post treatment (P<0.0005).
Likewise, the mean haematocrit decreased from 0.4 to before the onset of losartan therapy was not different between the two groups ( Table 3) . In Group A, the 0.35 (P<0.0005).
Effect ( Table 3) . Over the but one. Moreover, haemoglobin concentrations decreased more than 10 g/l in 14/18 patients. Such a 3 months, serum creatinine did not change in Group A (188 mmol/l±61 vs 190 mmol/l±71; P=NS), but consistent decline in haemoglobin is unlikely to be fortuitous. increased from 158 mmol/l±78 to 172 mmol/l±80 in Group B (P<0.005). The mean serum potassium conPlasma volume changes are unlikely to explain the changes in haematocrit observed during losartan centrations increased in the two groups from the beginning to the end of the study, but these changes therapy because we did not observe any changes in serum protein concentrations and there was no correlawere not statistically significant (4.2 mmol/l±0.4 vs 4.4 mmol/l±0.5 in Group A; 4.3 mmol/l±0.4 vs tion between the changes in haemoglobin and the changes in plasma concentrations. In addition, diuretic 4.5 mmol/l±0.5 in Group B).
Mean plasma protein concentrations were not therapy was not modified over the course of the study. In cases where the serum creatinine concentrations different before and after losartan therapy (67.1 g/l vs 67 g/l and 69 g/l vs 69.6 g/l in Group A and Group B, significantly increased after 3 months of losartan therapy, the decrease in renal function was not suffirespectively) (P=NS)). Two patients in Group A and one patient in Group B were treated with furosemide cient to explain the decrease in haemoglobin concentration. Moreover, we did not find any correlation at the beginning and throughout the study. No additional antihypertensive treatment was prescribed between the changes in serum creatinine concentrations and the changes in haematocrit haemoglobin concenduring the study for any patient.
There was no correlation between the changes in trations. This suggests that the influence of losartan on haemoglobin concentration is independent of allohaemoglobin and serum creatinine concentration nor between the changes in haemoglobin and plasma pro-graft function in renal transplant recipients.
A significant decrease in haematocrit has been tein concentrations ( Figures 1 and 2 . In subsequent studies, The current results suggest that losartan decreases significant decreases in haemoglobin and haematocrit haemoglobin concentration in renal transplant recipiwith enalapril therapy were observed in patients with ents. Although this study is a retrospective analysis renal insufficiency and in 30% of renal transplant and is lacking a control group, there is sufficient recipients treated with this agent for hypertension [10] . evidence to indicate that a randomized, prospective Few studies have investigated the impact of losartan study, which addresses the effect of losartan on haemoon haematology. In 1995, Shand et al.
[17] reported globin concentration, should be performed. Namely, on the effects of losartan on haematology and haemorrheology in elderly patients with primary hypertension. No significant change in haemoglobin was observed. Shaw et al. [18] also reported that losartan therapy did not modify haemoglobin levels in hypertensive patients with renal impairment. In our study, haemoglobin concentration was not influenced by losartan in patients previously undergoing ACE inhibitor therapy. This result suggests that Fig. 1 . Relationship between the variation in plasma protides con-mechanisms whereby losartan and ACE inhibitors centrations and the variation in haemoglobin concentrations in decrease the haematocrit are similar. However, it is patients of group B. y=−0.422×+16; r=0.02.
interesting to note that anaemia occurs in~30% of renal transplant recipients treated with ACE inhibitors while 94% of our patients undergoing losartan therapy experienced a decrease in haemoglobin concentration.
Mechanisms whereby ACE inhibitors and angiotensin II receptor antagonists decrease the haematocrit are unknown. It is well known that the reninangiotensin system influences EPO synthesis. In rodents, hypoxia increased plasma levels of both EPO and renin. Administration of homologous renin increased plasma EPO levels and this response was abolished by pre-treatment with captopril and restored by angiotensin II infusion [19] . Fried et al. demon- Fig. 2 . Relationship between the variation in serum creatinine con-strated that angiotensin II increased EPO levels in centrations and the variation in haemoglobin concentration. y= −0.021×+16.5; r=0.001.
anaemic animals [20] . In transplant recipients, produc-itors and response to enalapril. Transplant Proc 1994; 26: tion of renin from native kidneys is increased and in [280] [281] those with PTE, concentrations of renin and EPO in 
